07:00 , Jul 25, 2016 |  BC Week In Review  |  Company News

Asklepion Pharmaceuticals, Retrophin deal

Retrophin acquired a liquid formulation of ursodeoxycholic acid (UDCA) from Asklepion. Solid formulations of UDCA, a naturally occurring bile acid, are available as generics to treat primary biliary cholangitis (PBC). Retrophin said it aims to...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
01:49 , Oct 24, 2015 |  BC Extra  |  Top Story

FDA approves Alexion's Strensiq

FDA approved Strensiq asfotase alfa from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) to treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP) and granted the company a Priority Review voucher through the agency's rare pediatric disease Priority Review voucher...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Company News

Retrophin, Sanofi gastrointestinal news

Retrophin sold its rare pediatric disease Priority Review voucher to Sanofi for $245 million. Retrophin will receive $150 million up front, plus $47.5 million in 2016 and $47.5 million in 2017. Retrophin gained the voucher...
07:00 , Jun 1, 2015 |  BioCentury  |  Finance

Valuing vouchers

With the clock ticking on FDA's rare pediatric disease Priority Review voucher program and only one left unsold, it's hard to say whether the huge step-ups in valuations are a function of scarcity, or a...
07:00 , Apr 6, 2015 |  BioCentury  |  Finance

Up, up and acquired

For the first time since 1Q14, none of the biotech market cap segments fell. While the $200-$499 million tier treaded water, all other segments finished in the black, led by the $1-$4.9 billion segment. Large...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Clinical News

Cholbam cholic acid regulatory update

FDA approved an NDA for Cholbam cholic acid from Asklepion to treat bile acid synthesis disorders due to single enzyme defects in pediatric and adult patients and as an adjuvant to treat peroxisomal disorders, including...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Company News

Asklepion Pharmaceuticals, Retrophin deal

Retrophin will acquire Cholbam cholic acid from Asklepion following FDA approval of the product to treat bile acid synthesis disorders due to single enzyme defects and as an adjuvant to treat peroxisomal disorders, including Zellweger...
02:03 , Mar 20, 2015 |  BC Extra  |  Financial News

Funding roundup: Esperion, Retrophin, Assembly, Concert

Esperion Therapeutics Inc. (NASDAQ:ESPR), Retrophin Inc. (NASDAQ:RTRX), Assembly Biosciences Inc. (NASDAQ:ASMB) and Concert Pharmaceuticals Inc. (NASDAQ:CNCE) raised $430 million in follow-on offerings since market close Wednesday. Esperion raised $175 million through the sale of 1.8...
02:04 , Mar 19, 2015 |  BC Extra  |  Top Story

Stakeholders aiming to renew pediatric voucher program

FDA issued its third Priority Review voucher under its pediatric disease voucher program Tuesday, which triggers a 12-month clock until the pilot program ends. The program is intended to give pharma companies incentives to develop...